As part of our Advocacy work, the CSPA often prepares submissions on consultations run by governments across Canada on important topics that affect skin patients. 

The CSPA provided feedback to Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) about the importance of a flexible and updated approach to covering biologics in the province, including biosimilars. The Quebec government recently implemented a biosimilar policy and restricted the use of manufacturer co-pay cards to help achieve its policy goals of saving money and increasing the use of biosimilar medications where they are available. This letter was supported by the Canadian Association of Psoriasis Patients, the Canadian Psoriasis Network and Hidradenitis & Me Support Group. 
Read our letter here.
CSPA supported a joint submission to the federal government's rare disease drug strategy consultation in March 2021 asking the federal government to include cancers - and rare cancers, in particular - in the strategy.  
The CSPA signed on to a joint letter from cancer patient organizations earlier this year regarding increases to the Canada Health Transfer. A copy of the letter was sent to the minister of health, deputy minister, and Chief Medical Officer or Chief Public Health Officer of each province

CSPA Federal 2021 Pre-budget Submission - February 2021 (pdf)

PMPRB Guidelines Submission - August 2020 (pdf)

CSPA Federal 2021 pre-budget submission - August 2020 (pdf)

Ontario Pre-Budget Submission - March 2020 (pdf)

PMPRB Submission Guidelines Consultation (Drug Pricing) - Feb 2020  (pdf)


Consider supporting the work of the CSPA with a donation


We are proud to partner with the Canadian Association of Psoriasis Patients

Find out more about CAPP and the work they do for Canadian Psoriasis patients and their familes.

Contact Us